<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36556059</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>24</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle><i>Lactobacillus gasseri</i> LA806 Supplementation in Patients with Irritable Bowel Syndrome: A Multicenter Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">7446</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm11247446</ELocationID><Abstract><AbstractText>The potential benefits of Lactobacillus gasseri LA806 in IBS were previously identified in a comprehensive preclinical research program. The purpose of this multicenter study was to explore in real-life conditions changes in IBS symptoms and quality of life in patients receiving a 4-week supplementation with L. gasseri LA806. Altogether 119 patients meeting Rome IV criteria for IBS were included, of whom 118 received the supplement. The majority of patients (71.8% (95% CI 63.6&#x2212;79.9%)) manifested a &#x2265;30% decrease in abdominal pain at 4 weeks, the mean abdominal pain score diminishing by 54.2% (from 5.3 &#xb1; 2.2 to 2.2 &#xb1; 2.4, p &lt; 0.0001). A statistically significant decrease in abdominal pain was seen as early as the first week. A decrease of &#x2265;30% in both abdominal pain score and global IBS symptom score was attained in 61.5% of patients (95% CI 51.7&#x2212;71.2%). The mean IBS-SSS score fell by 152 &#xb1; 112 points (p = 0.001), with symptoms being attenuated in 85% of patients (CGI-I). Supplementation led to a 10-fold decrease in the number of patients reporting severe IBS symptoms. The concomitant intake of antidiarrheals, antispasmodics and analgesics decreased and quality of life scores significantly improved. These preliminary results warrant confirmation by a randomized, placebo-controlled study that this study will allow a better design.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ait Abdellah</LastName><ForeName>Samira</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>PiLeJe Laboratoire, 75015 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scanzi</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre Hospitalier de Thiers, 63300 Thiers, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMR INSERM 1107, Neuro-Dol, Faculty of Medicine, Clermont-Auvergne University, 63000 Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gal</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>PiLeJe Laboratoire, 75015 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cabinet M&#xe9;dical, 76130 Mont-Saint-Aignan, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beck</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cabinet M&#xe9;dical, 31240 L'Union, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ojetti</LastName><ForeName>Veronica</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Emergency Medicine Department, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Catholic University, 00165 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">abdominal pain</Keyword><Keyword MajorTopicYN="N">functional disease</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">microbiota</Keyword><Keyword MajorTopicYN="N">probiotics</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword></KeywordList><CoiStatement>S.A.A. and C.G. are employed by Pileje Laboratoire. M.M., M.B. have no conflicts of interest to declare. J.S. has received consulting and lecture fees from PiLeJe Laboratoire. V.O. received consulting fees from PiLeJe Laboratoire.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>23</Day><Hour>1</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36556059</ArticleId><ArticleId IdType="pmc">PMC9787120</ArticleId><ArticleId IdType="doi">10.3390/jcm11247446</ArticleId><ArticleId IdType="pii">jcm11247446</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ducrott&#xe9; P., Sawant P., Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J. Gastroenterol. 2012;18:4012&#x2013;4018. doi: 10.3748/wjg.v18.i30.4012.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i30.4012</ArticleId><ArticleId IdType="pmc">PMC3419998</ArticleId><ArticleId IdType="pubmed">22912552</ArticleId></ArticleIdList></Reference><Reference><Citation>Black C.J., Ford A.C. Global burden of irritable bowel syndrome: Trends, predictions and risk factors. Nat. Rev. Gastroenterol. Hepatol. 2020;17:473&#x2013;486. doi: 10.1038/s41575-020-0286-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-020-0286-8</ArticleId><ArticleId IdType="pubmed">32296140</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R. Bowel Disorders. Gastroenterology. 2016;150:1393&#x2013;1407.e5. doi: 10.1053/j.gastro.2016.02.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.031</ArticleId><ArticleId IdType="pubmed">27144627</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell R.M., Ford A.C. Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. Clin. Gastroenterol. Hepatol. 2012;10:712&#x2013;721.e4. doi: 10.1016/j.cgh.2012.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2012.02.029</ArticleId><ArticleId IdType="pubmed">22426087</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber A.D., Bangdiwala S.I., Drossman D.A., Ghoshal U.C., Simren M., Tack J., Whitehead W.E., Dumitrascu D.L., Fang X., Fukudo S., et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology. 2021;160:99&#x2013;114.e3. doi: 10.1053/j.gastro.2020.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.04.014</ArticleId><ArticleId IdType="pubmed">32294476</ArticleId></ArticleIdList></Reference><Reference><Citation>Palsson O.S., Whitehead W., T&#xf6;rnblom H., Sperber A.D., Simren M. Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom. Gastroenterology. 2020;158:1262&#x2013;1273.e3. doi: 10.1053/j.gastro.2019.12.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.12.021</ArticleId><ArticleId IdType="pubmed">31917991</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka P., Parr H., Barberio B., Black C.J., Savarino E.V., Ford A.C. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2020;5:908&#x2013;917. doi: 10.1016/S2468-1253(20)30217-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30217-X</ArticleId><ArticleId IdType="pubmed">32702295</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel B.M.R., Bolus R., Harris L.A., Lucak S., Chey W.D., Sayuk G., Esrailian E., Lembo A., Karsan H., Tillisch K., et al. Characterizing abdominal pain in IBS: Guidance for study inclusion criteria, outcome measurement and clinical practice. Aliment. Pharmacol. Ther. 2010;32:1192&#x2013;1202. doi: 10.1111/j.1365-2036.2010.04443.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2010.04443.x</ArticleId><ArticleId IdType="pmc">PMC4118306</ArticleId><ArticleId IdType="pubmed">20807217</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel B., Bolus R., Harris L.A., Lucak S., Naliboff B., Esrailian E., Chey W.D., Lembo A., Karsan H., Tillisch K., et al. Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale. Aliment. Pharmacol. Ther. 2009;30:1159&#x2013;1170. doi: 10.1111/j.1365-2036.2009.04144.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2009.04144.x</ArticleId><ArticleId IdType="pmc">PMC2793273</ArticleId><ArticleId IdType="pubmed">19751360</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. CDER. MCCRAYK  Irritable Bowel Syndrome&#x2014;Clinical Evaluation of Drugs for Treatment.  [(accessed on 4 October 2022)];2012  Available online:  https://www.fda.gov/media/78622/download.</Citation></Reference><Reference><Citation>Lee Y.-T., Hu L.-Y., Shen C.-C., Huang M.-W., Tsai S.-J., Yang A.C., Hu C.-K., Perng C.-L., Huang Y.-S., Hung J.-H. Risk of psychiatric disorders following Irritable Bowel Syndrome: A nationwide population-based cohort study. PLoS ONE. 2015;10:e0133283. doi: 10.1371/journal.pone.0133283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0133283</ArticleId><ArticleId IdType="pmc">PMC4519183</ArticleId><ArticleId IdType="pubmed">26222511</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews C.N., Bradette M. Diarrhea-predominant irritable bowel syndrome: Medical management update. J. Can. Assoc. Gastroenterol. 2020;3:e37&#x2013;e48. doi: 10.1093/jcag/gwz034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jcag/gwz034</ArticleId><ArticleId IdType="pmc">PMC7678738</ArticleId><ArticleId IdType="pubmed">33241185</ArticleId></ArticleIdList></Reference><Reference><Citation>Hungin A.P.S., Mulligan C., Pot B., Whorwell P., Agr&#xe9;us L., Fracasso P., Lionis C., Mendive J., Philippart de Foy J.-M., Rubin G., et al. Systematic review: Probiotics in the management of lower gastrointestinal symptoms in clinical practice&#x2014;An evidence-based international guide. Aliment. Pharmacol. Ther. 2013;38:864&#x2013;886. doi: 10.1111/apt.12460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12460</ArticleId><ArticleId IdType="pmc">PMC3925990</ArticleId><ArticleId IdType="pubmed">23981066</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee B.J., Bak Y.-T. Irritable bowel syndrome, gut microbiota and probiotics. J. Neurogastroenterol. Motil. 2011;17:252&#x2013;266. doi: 10.5056/jnm.2011.17.3.252.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm.2011.17.3.252</ArticleId><ArticleId IdType="pmc">PMC3155061</ArticleId><ArticleId IdType="pubmed">21860817</ArticleId></ArticleIdList></Reference><Reference><Citation>Distrutti E., Monaldi L., Ricci P., Fiorucci S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J. Gastroenterol. 2016;22:2219&#x2013;2241. doi: 10.3748/wjg.v22.i7.2219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i7.2219</ArticleId><ArticleId IdType="pmc">PMC4734998</ArticleId><ArticleId IdType="pubmed">26900286</ArticleId></ArticleIdList></Reference><Reference><Citation>Alard J., Peucelle V., Boutillier D., Breton J., Kuylle S., Pot B., Holowacz S., Grangette C. New probiotic strains for inflammatory bowel disease management identified by combining in vitro and in vivo approaches. Benef. Microbes. 2018;9:317&#x2013;331. doi: 10.3920/BM2017.0097.</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2017.0097</ArticleId><ArticleId IdType="pubmed">29488412</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P.P., Chin V.K., Looi C.Y., Wong W.F., Madhavan P., Yong V.C. The Microbiome and Irritable Bowel Syndrome&#x2014;A Review on the Pathophysiology, Current Research and Future Therapy. Front. Microbiol. 2019;10:1136. doi: 10.3389/fmicb.2019.01136.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.01136</ArticleId><ArticleId IdType="pmc">PMC6579922</ArticleId><ArticleId IdType="pubmed">31244784</ArticleId></ArticleIdList></Reference><Reference><Citation>Carco C., Young W., Gearry R.B., Talley N.J., McNabb W.C., Roy N.C. Increasing evidence that irritable bowel syndrome and functional gastrointestinal disorders have a microbial pathogenesis. Front. Cell. Infect. Microbiol. 2020;10:468. doi: 10.3389/fcimb.2020.00468.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.00468</ArticleId><ArticleId IdType="pmc">PMC7509092</ArticleId><ArticleId IdType="pubmed">33014892</ArticleId></ArticleIdList></Reference><Reference><Citation>Simr&#xe9;n M., Barbara G., Flint H.J., Spiegel B.M.R., Spiller R.C., Vanner S., Verdu E.F., Whorwell P.J., Zoetendal E.G. Intestinal microbiota in functional bowel disorders: A Rome foundation report. Gut. 2013;62:159&#x2013;176. doi: 10.1136/gutjnl-2012-302167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2012-302167</ArticleId><ArticleId IdType="pmc">PMC3551212</ArticleId><ArticleId IdType="pubmed">22730468</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiequn B., Guanqun C., Shuo Z. Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: A meta-analysis. Intern. Med. 2015;54:243&#x2013;249. doi: 10.2169/internalmedicine.54.2710.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.54.2710</ArticleId><ArticleId IdType="pubmed">25748731</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B., Liang L., Deng H., Guo J., Shu H., Zhang L. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis. Front. Pharmacol. 2020;11:332. doi: 10.3389/fphar.2020.00332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00332</ArticleId><ArticleId IdType="pmc">PMC7147251</ArticleId><ArticleId IdType="pubmed">32317962</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J.-R., Kong C.-F., Qu X.-K., Deng C., Lou Y.-N., Jia L.-Q. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis. Saudi J. Gastroenterol. 2020;26:66&#x2013;77. doi: 10.4103/sjg.SJG_384_19.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/sjg.SJG_384_19</ArticleId><ArticleId IdType="pmc">PMC7279071</ArticleId><ArticleId IdType="pubmed">31898645</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Morvan de Sequeira C., Kaeber M., Cekin S.E., Enck P., Mack I. The effect of probiotics on quality of life, depression and anxiety in patients with irritable bowel syndrome: A systematic review and meta-analysis. JCM. 2021;10:3497. doi: 10.3390/jcm10163497.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10163497</ArticleId><ArticleId IdType="pmc">PMC8397103</ArticleId><ArticleId IdType="pubmed">34441793</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji M., Huang H., Lan X., Shi Z. Correlation between intestinal microflora in irritable bowel syndrome and severity. Dis. Markers. 2022;2022:1031844. doi: 10.1155/2022/1031844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/1031844</ArticleId><ArticleId IdType="pmc">PMC9132690</ArticleId><ArticleId IdType="pubmed">35634439</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami K., Habukawa C., Nobuta Y., Moriguchi N., Takemura T. The effect of Lactobacillus brevis KB290 against irritable bowel syndrome: A placebo-controlled double-blind crossover trial. Biopsychosoc. Med. 2012;6:16. doi: 10.1186/1751-0759-6-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1751-0759-6-16</ArticleId><ArticleId IdType="pmc">PMC3489517</ArticleId><ArticleId IdType="pubmed">22863114</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobutani K., Sawada D., Fujiwara S., Kuwano Y., Nishida K., Nakayama J., Kutsumi H., Azuma T., Rokutan K. The effects of administration of the Lactobacillus gasseri strain CP2305 on quality of life, clinical symptoms and changes in gene expression in patients with irritable bowel syndrome. J. Appl. Microbiol. 2017;122:212&#x2013;224. doi: 10.1111/jam.13329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jam.13329</ArticleId><ArticleId IdType="pubmed">27761980</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin S.P., Choi Y.M., Kim W.H., Hong S.P., Park J.-M., Kim J., Kwon O., Lee E.H., Hahm K.B. A double blind, placebo-controlled, randomized clinical trial that breast milk derived-Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome. J. Clin. Biochem. Nutr. 2018;62:179&#x2013;186. doi: 10.3164/jcbn.17-73.</Citation><ArticleIdList><ArticleId IdType="doi">10.3164/jcbn.17-73</ArticleId><ArticleId IdType="pmc">PMC5874236</ArticleId><ArticleId IdType="pubmed">29610559</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh J.H., Jang Y.S., Kang D., Chang D.K., Min Y.W. Efficacy and safety of new lactobacilli probiotics for unconstipated irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. Nutrients. 2019;11:2887. doi: 10.3390/nu11122887.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11122887</ArticleId><ArticleId IdType="pmc">PMC6950464</ArticleId><ArticleId IdType="pubmed">31783597</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis E.D., Antony J.M., Crowley D.C., Piano A., Bhardwaj R., Tompkins T.A., Evans M. Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in alleviating symptoms of irritable bowel syndrome (IBS): A randomized, placebo-controlled study. Nutrients. 2020;12:1159. doi: 10.3390/nu12041159.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12041159</ArticleId><ArticleId IdType="pmc">PMC7230591</ArticleId><ArticleId IdType="pubmed">32326347</ArticleId></ArticleIdList></Reference><Reference><Citation>Martoni C.J., Srivastava S., Leyer G.J. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: Randomized controlled trial. Nutrients. 2020;12:363. doi: 10.3390/nu12020363.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12020363</ArticleId><ArticleId IdType="pmc">PMC7071206</ArticleId><ArticleId IdType="pubmed">32019158</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabat&#xe9; J.-M., Iglicki F. Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome. WJG. 2022;28:732&#x2013;744. doi: 10.3748/wjg.v28.i7.732.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v28.i7.732</ArticleId><ArticleId IdType="pmc">PMC8891724</ArticleId><ArticleId IdType="pubmed">35317278</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.Y., Park Y.J., Lee H.J., Park M.Y., Kwon O. Effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome: A randomized, double-blind, placebo-controlled, dose-finding trial. Food Sci. Biotechnol. 2018;27:853&#x2013;857. doi: 10.1007/s10068-017-0296-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10068-017-0296-7</ArticleId><ArticleId IdType="pmc">PMC6049675</ArticleId><ArticleId IdType="pubmed">30263811</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaufrand C., Holowacz S., Perez A., Kuylle S., Theodorou V. Lactobacillus gasseri LA806 suppresses visceral hypersensitivity and barrier disruption induced by chronic stress in rats. Abstracts of the 10th Workshop on Probiotics and Prebiotics. Ann. Nutr. Metab. 2019;74:14.</Citation></Reference><Reference><Citation>Blanchet F., Rault L., Peton V., Le Loir Y., Blondeau C., Lenoir L., Dubourdeaux M., Even S. Heat inactivation partially preserved barrier and immunomodulatory effects of Lactobacillus gasseri LA806 in an in vitro model of bovine mastitis. Benef. Microbes. 2021;12:95&#x2013;106. doi: 10.3920/BM2020.0146.</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2020.0146</ArticleId><ArticleId IdType="pubmed">33393446</ArticleId></ArticleIdList></Reference><Reference><Citation>Authier H., Salon M., Rahabi M., Bertrand B., Blondeau C., Kuylle S., Holowacz S., Coste A. Oral administration of Lactobacillus helveticus LA401 and Lactobacillus gasseri LA806 combination attenuates oesophageal and gastrointestinal candidiasis and consequent gut inflammation in mice. J. Fungi. 2021;7:57. doi: 10.3390/jof7010057.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jof7010057</ArticleId><ArticleId IdType="pmc">PMC7830595</ArticleId><ArticleId IdType="pubmed">33467443</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy B., Patel N. Rome criteria and a diagnostic approach to irritable bowel syndrome. JCM. 2017;6:99. doi: 10.3390/jcm6110099.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm6110099</ArticleId><ArticleId IdType="pmc">PMC5704116</ArticleId><ArticleId IdType="pubmed">29072609</ArticleId></ArticleIdList></Reference><Reference><Citation>Heaton K.W., Radvan J., Cripps H., Mountford R.A., Braddon F.E., Hughes A.O. Defecation frequency and timing, and stool form in the general population: A prospective study. Gut. 1992;33:818&#x2013;824. doi: 10.1136/gut.33.6.818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.33.6.818</ArticleId><ArticleId IdType="pmc">PMC1379343</ArticleId><ArticleId IdType="pubmed">1624166</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis C.Y., Morris J., Whorwell P.J. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther. 1997;11:395&#x2013;402. doi: 10.1046/j.1365-2036.1997.142318000.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.1997.142318000.x</ArticleId><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglielmetti S., Mora D., Gschwender M., Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life&#x2014;A double-blind, placebo-controlled study. Aliment. Pharmacol. Ther. 2011;33:1123&#x2013;1132. doi: 10.1111/j.1365-2036.2011.04633.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2011.04633.x</ArticleId><ArticleId IdType="pubmed">21418261</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen N., Andersen N.N., V&#xe9;gh Z., Jensen L., Ankersen D.V., Felding M., Simonsen M.H., Burisch J., Munkholm P. Ehealth: Low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome. World J. Gastroenterol. 2014;20:16215&#x2013;16226. doi: 10.3748/wjg.v20.i43.16215.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i43.16215</ArticleId><ArticleId IdType="pmc">PMC4239510</ArticleId><ArticleId IdType="pubmed">25473176</ArticleId></ArticleIdList></Reference><Reference><Citation>Andresen V., Gschossmann J., Layer P. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: A multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol. Hepatol. 2020;5:658&#x2013;666. doi: 10.1016/S2468-1253(20)30056-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30056-X</ArticleId><ArticleId IdType="pubmed">32277872</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>